



A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2)

OPEN ACCESS

Edited by:

Longxiang Su,
Peking Union Medical College
Hospital (CAMS), China

Reviewed by:

Fernando Scudiero,
Bolognini Hospital, Italy
Renato Bernardini,
University of Catania, Italy
Stefano Centanni,
University of Milan, Italy

*Correspondence:

Nadia Rubis
nadia.rubis@marionegri.it

†These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Infectious Diseases - Surveillance,
Prevention and Treatment,
a section of the journal
Frontiers in Medicine

Received: 29 September 2021

Accepted: 18 March 2022

Published: 22 April 2022

Citation:

Consolaro E, Suter F, Rubis N,
Pedroni S, Moroni C, Pastò E,
Paganini MV, Pravettoni G,
Cantarelli U, Perico N, Perna A,
Peracchi T, Ruggenti P and
Remuzzi G (2022) A Home-Treatment
Algorithm Based on Anti-inflammatory
Drugs to Prevent Hospitalization of
Patients With Early COVID-19: A
Matched-Cohort Study (COVER 2).
Front. Med. 9:785785.
doi: 10.3389/fmed.2022.785785

Elena Consolaro¹, Fredy Suter², Nadia Rubis^{3*}, Stefania Pedroni¹, Chiara Moroni¹,
Elena Pastò¹, Maria Vittoria Paganini¹, Grazia Pravettoni⁴, Umberto Cantarelli⁵,
Norberto Perico^{3†}, Annalisa Perna³, Tobia Peracchi³, Piero Ruggenti^{2,3†} and
Giuseppe Remuzzi^{3†}

¹ Agenzia di Tutela della Salute (ATS) Insubria, Varese, Italy, ² Azienda Socio-Sanitaria Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy, ³ Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy, ⁴ Ospedale Circolo di Busto Arsizio, Varese, Italy, ⁵ Azienda Sanitaria Locale (ASL) Teramo, Teramo, Italy

Background and Aim: While considerable success has been achieved in the management of patients hospitalized with severe coronavirus disease 2019 (COVID-19), far less progress has been made with early outpatient treatment. We assessed whether the implementation of a home treatment algorithm—designed based on a pathophysiologic and pharmacologic rationale—and including non-steroidal anti-inflammatory drugs, especially relatively selective cyclooxygenase-2 inhibitors and, when needed, corticosteroids, anticoagulants, oxygen therapy and antibiotics—at the very onset of mild COVID-19 symptoms could effectively reduce hospital admissions.

Methods: This fully academic, matched-cohort study evaluated outcomes in 108 consecutive consenting patients with mild COVID-19, managed at home by their family doctors between January 2021 and May 2021, according to the proposed treatment algorithm and in 108 age-, sex-, and comorbidities-matched patients on other therapeutic schedules (ClinicalTrials.gov: NCT04854824). The primary outcome was COVID-19-related hospitalization. Analyses were by intention-to-treat.

Results: One (0.9%) patient in the “recommended” cohort and 12 (11.1%) in the “control” cohort were admitted to hospital ($P = 0.0136$). The proposed algorithm reduced the cumulative length of hospital stays by 85% (from 141 to 19 days) as well as related costs (from €60.316 to €9.058). Only 9.8 patients needed to be treated with the recommended algorithm to prevent one hospitalization event. The rate of resolution of major symptoms was numerically—but not significantly—higher in the “recommended” than in the “control” cohort (97.2 vs. 93.5%, respectively; $P = 0.322$). Other symptoms lingered in a smaller proportion of patients in the “recommended” than in the “control” cohort (20.4 vs. 63.9%, respectively; $P < 0.001$), and for a shorter period.

Conclusion: The adoption of the proposed outpatient treatment algorithm during the early, mild phase of COVID-19 reduced the incidence of subsequent hospitalization and related costs.

Keywords: COVID-19, SARS-CoV-2, hospitalization, outpatients, at home management

INTRODUCTION

Over the past 2 years the novel coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), which causes coronavirus disease 2019 (COVID-19), has quickly spread globally, reaching pandemic proportions (1). Through genetic evolution, resulting in multiple variants (2), SARS-CoV-2 has been responsible for several pandemic waves worldwide (1). The clinical manifestations of COVID-19 disease are broad, spanning asymptomatic infection, mild upper respiratory tract and/or mild extrapulmonary symptoms, and including severe pneumonia, acute respiratory distress syndrome and multiorgan system dysfunction, and even death (3, 4). During the early phase of COVID-19, when patients are at home, they are usually not seriously ill with acute respiratory distress, but present a variety of initially mild/moderate symptoms, including fever, cough, tiredness, shortness of breath and chills, a sore throat, headache, musculoskeletal pain, and a new loss of taste and smell (5).

While drug/biological treatment options for severely ill COVID-19 patients requiring hospitalization are now available (6–11), interventions that can be administered by primary care physicians at home have been more difficult to determine and controversial (12). Nonetheless, the early initiation of treatment for COVID-19 might improve clinical outcomes, providing a potential window for immediate benefits by intervening before the development of severe disease, and possibly limiting or preventing the risk of patient hospitalization.

Although guidelines or recommendations for managing patients with suspected or confirmed COVID-19 in the community have recently been made available by national health authorities (13, 14), most family doctors initially treated their patients with a variety of treatment regimens they believed appropriate based on their clinical expertise. Based on the growing available knowledge on the pathophysiology underlying the mild/moderate symptoms encountered at the onset of the illness (15, 16), we recently published a proposed regimen of simple drugs that should, theoretically, fit these mechanisms better (17). The proposed treatment recommendations (17) are based on three pillars: (i) intervene at the very onset of mild/moderate symptoms at home; (ii) start therapy as early as possible after the family doctor has been contacted by the patient, without awaiting the results of a nasopharyngeal swab; (iii) rely on non-steroidal anti-inflammatory drugs, especially relatively selective cyclooxygenase-2 (COX-2) inhibitors (18, 19), an approach that aims to limit excessive host inflammatory responses to viral infection (16, 17).

In a recent academic matched-cohort study (20), we found that early treatment of COVID-19 patients at home by their

family doctors, according to the proposed recommendation regimen, almost completely prevented the need for hospital admission due to progression toward more severe illness (2 out of 90 patients), compared to patients in the “control” cohort, who were treated at home according to their family physicians’ assessments (13 out of 90 patients). However, the rate of hospitalization was a secondary outcome of the study, and the possibility that this is a random finding cannot be definitively ruled out. Thus, we considered the observed reduction in patient hospitalizations a hypothesis-generating finding that provides the background for the present, new matched-cohort study. The primary aim of this study was to test the effect of COVID-19 treatment at home on this outcome, according to the proposed recommendation algorithm.

MATERIALS AND METHODS

Study Design and Participants

This is an observational study that involved two matched cohorts of COVID-19 patients.

The “recommended algorithm” cohort included 108 patients treated at home by their family physicians who expressed interest in participating in the study and followed the published proposed treatment recommendation (17). They were from the Varese, Bergamo, and Teramo provinces (Italy) and prospectively enrolled their patients between January and May 2021. These family doctors applied the recommended algorithm at the onset of symptoms, or within a few days of being contacted by patients. The physicians provided patients with detailed information about the objectives and design of the study and collected signed consent forms. Family doctors were asked to complete an online questionnaire with information on the outcomes of COVID-19 symptoms/illness that are relevant to addressing the primary, secondary and safety aims of the study. To this, the physicians filled the questionnaire based on the information they have previously periodically collected in their computerized medical records for each patient, starting from the first contact for early COVID-19 symptoms. The Istituto di Ricerche Farmacologiche Mario Negri IRCCS (Bergamo, Italy) coordinated the project, promoted through online institutional media. Male and female adults, aged ≥ 18 years, with early, mild symptoms of COVID-19, who started the recommended treatment without awaiting the results of a nasopharyngeal swab, if any, were eligible to participate in the study.

As a control cohort, 108 historic COVID-19 patients were considered retrospectively. These patients had been enrolled in the “Study of the Genetic Factors that Influence the Susceptibility to and Severity of COVID-19” (the ORIGIN study, conducted by the Istituto di Ricerche Farmacologiche Mario

Negri, IRCCS (ClinicalTrials.gov; NCT04799834), and treated at home by their family doctors with drug regimens that were not necessarily guided by those proposed in the recommendation algorithm. They were matched by age, sex, comorbidities (hypertension, diabetes, cardiovascular diseases, overweight, chronic kidney disease) with patients in the “recommended algorithm” cohort. Notably, the ORIGIN study collects, among other things, all clinical information intended for the analysis of the “recommended algorithm” cohort from the population of COVID-19 patients living in the province of Bergamo.

In both cohorts, subjects were excluded if they were considered in need of immediate hospitalization, by their family physician because of severe COVID-19 symptoms at onset.

Summary of the Recommended Algorithm for At-Home COVID-19 Treatment

Recommended treatments should start immediately when early COVID-19 symptoms appear, without awaiting the results of a nasopharyngeal swab, if any. The recommended drugs can be used unless contraindicated according to the summary of product characteristics.

I. Non-steroidal anti-inflammatory drugs (NSAIDs)

Relatively selective COX-2 inhibitors^{§#} (for myalgias and/or arthralgias or other painful symptoms)

[§] based on the ratio of concentrations of the various NSAIDs required to inhibit the activity of COX-1 and COX-2 by 50 percent (IC₅₀) in whole blood assays

[#] unless contraindicated

Nimesulide^{*}

100 mg b.i.d p.o, after a meal, for a maximum of 12 days.

Or

Celecoxib^{*}

Initial oral dose of 400 mg, followed by a second dose of 200 mg on the first day of therapy. In the following days, up to a maximum of 400 mg (200 mg twice a day) should be given as needed for a maximum of 12 days

^{*} Should the patient have a fever ($\geq 37.3^{\circ}\text{C}$) or develop laboratory signs of hepatotoxicity associated with nimesulide, or if there are contraindications to celecoxib, these drugs should be substituted with aspirin (a COX-1 and COX-2 inhibitor) (500 mg twice a day p.o.—after a meal). Patients receiving these treatments should also be given a proton pump inhibitor (e.g., lansoprazole—30 mg/day; or omeprazole—20 mg/day; or pantoprazole—20 mg/day).

Approximately 3 days after the onset of symptoms (or longer if the physician is seeing the patient for the first time), a series of hematochemical tests should be performed (blood cell count, D-dimer, CRP, creatinine, fasting blood glucose, ALT). Nimesulide/celecoxib (or aspirin) treatment can continue if inflammatory indexes (CRP, neutrophil count), ALT, and D-dimer are in the normal range.

II. Corticosteroids^{*}

Dexamethasone (for persistent fever or musculoskeletal pain or if hematochemical tests are repeated a few days later and there is even a mild increase in the inflammatory indexes—CRP,

neutrophil count –, or if the patient has a cough and oxygen saturation (SpO₂) <94–92% occur)

8 mg p.o. for 3 days, then tapered to 4 mg for a further 3 days, and then to 2 mg for 3 days. This makes a total of 42 mg dexamethasone over 9 days.

^{*}The duration of corticosteroid treatment also depends on the clinical evolution of the disease

III. Anticoagulants

Low-molecular weight (LMW) heparin^{*} (when the hematochemical tests show even a mild increase in D-dimer, or for thromboembolism prophylaxis for bedridden patients)

Enoxaparin, at the prophylactic daily dose of 4,000 U.I subcutaneously—i.e., 40 mg enoxaparin. Treatment recommended for at least 7–14 days, independently of the patient recovering mobility.

^{*}unless contraindicated (e.g., ongoing bleeding or platelet count <25 × 10⁹/L)

IV. Oxygen therapy

Gentle oxygen supply in the early phase of the disease, possibly before pulmonary symptoms manifest, in the presence of progressively decreasing oxygen saturation—as indicated by an oximeter—or following a first episode of dyspnoea or wheezing.

Conventional oxygen therapy is suggested when the respiratory rate is >14/min and oxygen saturation (SpO₂) <94–92%, but is required with SpO₂ <90% at room air. With liquid oxygen, start with 8–10 liter/min and monitor SpO₂ every 3–4 h. Titrate oxygen flow rate to reach target SpO₂ >94%. Then the rate of oxygen administration can be reduced to 4–5 liter/min (but continue SpO₂ monitoring every 3–4 h). With gaseous O₂, start with 2.5–3.0 liter/min, but monitor SpO₂ more frequently than with liquid oxygen, and titrate flow rates to reach target SpO₂ >94%. Hospitalization could be considered, if feasible, when oxygen saturation (SpO₂) ≤90% at room air, despite conventional oxygen therapy.

V. Antibiotics

Azithromycin^{*} (with bacterial pneumonia or suspected secondary bacterial upper respiratory tract infections, or when hematochemical inflammatory indexes (CRP, neutrophil count) are markedly altered)

500 mg/day p.o. for 6–10 days depending on the clinical judgement

^{*} Should the patient be at risk of or have a history of cardiac arrhythmia or present other contraindications, cefixime (400 mg/day p.o for 6–10 days) or amoxicillin/clavulanic acid (1 gr three times a day for 6–10 days) can be considered as alternatives to azithromycin.

Outcome Variables

The primary outcome was the proportion of patients who required hospitalization due to clinical worsening of the illness in the two treatment cohorts. Clinical worsening was judged by the family doctors based on persistence of high fever ($\geq 38^{\circ}\text{C}$), or of cough, or instability of blood pressure/heart rate or breath frequency, so their patients were referred to the hospital. However, the final decision to hospitalize a patient

was taken by the hospital doctors in the Emergency Unit, after proper assessment.

Secondary outcomes included: (i) Compliance with the algorithm in the cohort that adopted the proposed treatment recommendations, defined as adherence to recommended schedule of treatment; (ii) Number of days between onset of symptoms and the start of anti-inflammatory therapy; (iii) The proportion of patients in the two cohorts with complete resolution of major symptoms (“complete remission”) defined as recovery from these symptoms: no fever, SpO₂ >94% and/or no dyspnea, cough, rhinitis, pain (myalgia, arthralgia, chest pain, headache, sore throat), vertigo, nausea, vomiting or diarrhea, sicca syndrome or red eyes; (iv) The proportion of patients in the two cohorts with persistent other symptoms, such as anosmia, ageusia/dysgeusia, lack of appetite, fatigue. In addition, the duration of these symptoms (<30 days, or 30 to 60, or >60 days) was evaluated; (v) Time (in days) spent in an intensive care unit, sub-intensive care unit, and ordinary units by patients who required hospital admission in the two cohorts; (vi) Cumulative hospitalization costs (in euro) for patients admitted to hospital in the two cohorts. Potential baseline confounders such as age, sex, and concomitant diseases that could increase the risk of severe COVID-19 illness were predefined (21–23). Moreover, serious (SAE) and non-serious adverse events (AE) related to the administered treatments according to recommendations were assessed. The severity/non-severity of the observed events and their causal relationships with treatments were determined by the family doctor in charge of the patients.

Samples Size and Statistical Analysis

Based on our recent findings (20), we assumed that the proportion of hospital admissions in the “historic control” cohort, when patients were treated by their family doctors according to drug regimens not necessarily guided by those proposed in our recommendation algorithm, is 0.1444, and that in the “recommended algorithm” cohort it is 0.0222. Based on the above assumption, a sample size of 85 patients per group (170 total) would achieve 80% power to detect a difference between the group proportions of 0.1222 (two-sided log rank test, alpha=0.05). Assuming a 20% drop-out rate, 106 per group (i.e., 212 total) needed to be included.

The “recommended algorithm” and “historic control” cohorts were expected to be sufficiently comparable at baseline. However, matching was carried out between the two groups (24). The SAS PROC LOGISTIC was used to calculate the predicted probability of the dependent variable—the Propensity Score—for each observation in the data set. This single score (between 0 and 1) represents the relationship between multiple characteristics (i.e., the following baseline variables: age, sex, and comorbidities) and the dependent variable (i.e., the treatment group) as a single characteristic. Then the propensity score represents the predicted probability of receiving treatment. Using the SAS %MACRO OneToManyMTCH, the 108 “recommended algorithm” individuals were matched to 108 “control” subjects with the closest propensity score. Moreover, to verify the robustness of the propensity score method described above, a further exploratory approach was used by employing the “teffects

iptw” STATA command to estimate the average treatment effect from observational data by inverse probability treatment weighting (IPTW), including 3,368 individuals (i.e., 3,260 subjects from the control ORIGIN database, and 108 from the “recommended treatment” cohort). In addition, a further explorative analysis based on the 3,368 subjects was performed using a multivariable logistic regression model. Covariate balance across the “recommended treatment” cohort ($n = 108$) and the whole “control” cohort ($n = 3,260$) was evaluated before and after matching (**Supplementary Table S1**) (25).

Continuous variables were analyzed through descriptive statistics and reported as mean (SD) or median [IQR], as appropriate. Within-group changes with respect to baseline were analyzed using the paired *t*-test or Wilcoxon signed-rank test, as appropriate. To determine the proportion of patients who required hospitalization, a log-rank test was used.

The cumulative costs of hospitalization in the two cohorts were the sum of the direct costs of stays in an ordinary ward, sub-intensive care unit and intensive care unit for the entire period of hospitalization. In particular, in each cohort the total number of days that all patients spent in each of the three units of the hospital was multiplied by the corresponding estimated direct cost of stay per day (i.e., €427, €582, and €1,278 per stay in an ordinary ward, and sub-intensive and intensive care units, respectively). Then the cumulative costs were calculated as the sum of the overall costs of stay in the three units. The direct cost per day was derived from data from a study on the management of COVID-19 patients admitted to hospital (Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy) and the resources used, performed by the Associazione Italiana Ingegneri Gestionali in Sanità (Castellanza, Varese, Italy) and presented at the LIUC Business School (Castellanza, Varese Italy) (<https://www.liucbs.it/>—Webinar COVID, 8 July 2020).

All analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, NC) and Stata 15 (StataCorp, College Station, TX). For the primary outcome, a *p*-value of 0.05 was considered to determine statistical significance. For the six secondary outcomes a Bonferroni-adjustment for multiple tests was used and a *p*-value of 0.0083 was used (26).

Ethical Aspects

The COVER 2 study was approved by the Ethical Committee of Insubria (Varese, Italy; 27 July 2021) and registered at ClinicalTrials.gov (NCT04854824). In COVER 2, participants in the “recommended algorithm” cohort provided written informed consent to their family doctors at enrolment. Subjects in the “control” cohort (from the ORIGIN database) signed a consent form to participate in the ORIGIN study, which also explicitly included consent to use their data for future studies, such as COVER 2.

RESULTS

Participants

Eight family doctors reported treating 108 consenting patients with early COVID-19 symptoms at home between January 2021 and May 2021, according to the proposed recommended

algorithm (17). All individuals in this “recommendation” cohort, had positive nasopharyngeal swabs, confirming SARS-CoV-2 infection. In 103 of 108 matched subjects identified in the ORIGIN dataset (“control” cohort) the onset of COVID-19 symptoms occurred between late February and July 2020, and in the other 5 participants between September 2020 and January 2021. SARS-CoV-2 infection was confirmed in all cases by a positive nasopharyngeal swab, when available and performed, or by a positive serological test several months after the resolution of COVID-19. These individuals were treated at home by their family physicians with drug regimens that were not necessarily guided by those proposed in the recommendation algorithm. The cohorts were comparable in terms of mean age and age range, with most subjects aged between 41 and 65 (Table 1). Females were more prevalent in both cohorts (57.4 and 64.8%). The concomitant diseases were well-distributed between the two groups, except for overweight/obesity, which were reported in a few more individuals in the “control” cohort. The most common symptoms at the onset of illness were fever (70.4 vs. 72.2%) and tiredness (68.5 vs. 76.9%), followed by cough (60.2 vs. 48.2%), and myalgia (48.2 vs. 53.7%) in both the “recommendation” and “control” cohorts (Table 1). More individuals in the “recommended algorithm” cohort had arthralgia (30.6 vs. 3.7%, $P = 0.001$), while ageusia was significantly more frequent in the “control” cohort (38.9 vs. 55.6%, $P = 0.020$). The distribution of dyspnea was similar between the two groups (25.9 vs. 31.5%, $P = 0.452$).

Primary Outcome

One of the 108 patients (0.9%) in the “recommended” cohort was hospitalized, compared to 12 of the 108 patients (11.1%) in the “control” cohort (Figure 1). The event rate was significantly lower in the “recommended” than in the “control” group (survival analysis for clustered data, $P = 0.0136$) (Figure 1). The patient in the “recommended” cohort was admitted to hospital due documented interstitial pneumonia (Table 2). This was the same reason for the hospitalization of all patients in the “control” cohort, except for one who was admitted with dyspnea due to documented pulmonary thromboembolism (Table 2).

To confirm these findings, explorative analysis was performed using the inverse probability weighting (IPTW) method, including 3,368 patients (i.e., 3,260 from the control ORIGIN database and 108 from the “recommended algorithm” cohort). The baseline characteristics of the 3,260 control cohort are provided in Supplementary Table S2. We found that the hospitalization rate in the “recommended algorithm” cohort was significantly lower than in the “control” cohort (-0.059 ; 95% CI, -0.077 to -0.041 ; $P < 0.0001$).

Secondary Outcomes

Seventy-four of 108 “recommended” cohort patients were treated with a relatively selective COX-2 inhibitor, such as nimesulide or celecoxib, while 15 patients were given aspirin (Table 3). Non-adherence to the recommended anti-inflammatory regimen was 24.07%, since 26 patients were prescribed other NSAIDs (ketoprofen, ibuprofen or paracetamol). In the “recommended” cohort, anti-inflammatory treatment with

TABLE 1 | Demographics and early symptoms associated with COVID-19 illness in the two treatment cohorts.


	Overall (<i>n</i> = 216)	Recommended treatment cohort (<i>n</i> = 108)	Control cohort (<i>n</i> = 108)	<i>P</i> -value
Demographic characteristics				
Age, years				
18–40	43 (19.90)	23 (21.30)	20 (18.52)	0.968
41–65	127 (58.80)	63 (58.34)	64 (59.26)	
66–75	23 (10.65)	11 (10.18)	12 (11.11)	
>75	23 (10.65)	11 (10.18)	12 (11.11)	
Mean age ± SD	53.3 ± 15.4	53.1 ± 15.8	53.5 ± 15.1	0.847
Males, <i>n</i> (%)	84 (38.89)	46 (42.59)	38 (35.18)	0.329
Comorbidities, <i>n</i> (%)				
Cardiovascular disease	19 (8.80)	8 (7.41)	11 (10.18)	0.652
Hypertension	51 (23.61)	23 (21.30)	28 (25.93)	0.522
Diabetes mellitus	5 (1.85)	1 (0.93)	4 (3.70)	0.369
Overweight/obesity*	33 (15.28)	11 (10.18)	22 (20.37)	0.057
Chronic kidney disease	1 (0.46)	1 (0.93)	0 (0)	1.000
Early symptoms, <i>n</i> (%)				
Fever	154 (71.30)	76 (70.37)	78 (72.22)	0.880
Myalgia	110 (50.92)	52 (48.15)	58 (53.70)	0.496
Arthralgia	37 (17.13)	33 (30.55)	4 (3.70)	0.001
Tiredness/exhaustion	157 (72.68)	74 (68.52)	83 (76.85)	0.222
Dyspnea	62 (28.70)	28 (25.93)	34 (31.48)	0.452
Chest pain	32 (14.81)	14 (12.96)	18 (16.67)	0.566
Headache	87 (40.28)	46 (42.59)	41 (37.96)	0.579
Lack of appetite	64 (29.63)	26 (24.07)	38 (35.18)	0.101
Cough	117 (54.17)	65 (60.18)	52 (48.15)	0.101
Sore throat	57 (26.39)	35 (32.41)	22 (20.37)	0.063
Rhinitis	59 (27.31)	31 (28.70)	28 (25.93)	0.760
Vomiting/nausea	33 (15.28)	13 (12.04)	20 (18.52)	0.256
Diarrhea	38 (17.59)	16 (14.81)	22 (20.37)	0.372
Red eyes	22 (10.18)	7 (6.48)	15 (13.89)	0.114
Vertigo	11 (5.09)	10 (9.26)	1 (0.93)	0.010
Sicca syndrome	1 (0.46)	1 (0.93)	0 (0)	1.000
Anosmia	88 (40.74)	37 (34.26)	51 (47.22)	0.071
Ageusia	102 (47.22)	42 (38.89)	60 (55.55)	0.020

Data are numbers (percentages).

*Overweight/obesity was defined as a body mass index ≥ 25 kg/m². Between-group differences were assessed by Fisher's exact test.

NSAIDs was prescribed by family physicians within a mean (\pm SD) of 1.7 ± 3.3 days after the onset of symptoms, except for paracetamol, which was self-administered by patients before contacting the doctor. At variance, in the “control” cohort only a small number of patients received relatively selective COX-2 inhibitors ($n = 4$) or aspirin ($n = 5$) (Table 3). Notably, in this cohort most patients were given paracetamol ($n = 74$), and the remainder ketoprofen or ibuprofen.

Corticosteroids were prescribed to 26 and 6.5% of patients in the “recommended” and “control” cohorts, respectively



($P < 0.001$) (Table 3). A median of 7 [IQR: 5–8.5] days elapsed between starting NSAID and corticosteroid prescriptions in the “recommended” group. More patients were treated with antibiotics in the “recommended” than in the “control” cohort ($P = 0.039$), while anticoagulants were prescribed in very few cases in either group (Table 3). Ten patients in the “recommended” cohort and two in the “control” cohort required oxygen supply at home due to decreasing oxygen saturation or following a first episode of dyspnea or wheezing ($P = 0.033$) (Table 3).

Almost all patients achieved resolution of the major symptoms (i.e., complete remission), and the event rate was numerically—but not significantly—higher in the recommended than in the “control” cohort ($P = 0.332$) (Table 4). On the other hand, the proportion of patients with other symptoms that were persistent, such as anosmia, ageusia/dysgeusia, lack of appetite and fatigue, was significantly lower in the “recommended” than in the “control” cohort (20.4 vs. 63.9%, respectively; $P < 0.001$) (Table 4). This difference was shown in the subgroups of patients in whom these symptoms persisted for 30 to 60 days or over 60 days (Table 4).

The single patient in the “recommended” cohort who was hospitalized was discharged after 19 days, compared to 12 ± 7 (range, 4–26) days in the 12 patients in the “control” cohort. The cumulative length of hospital stays in the latter cohort reached 141 days (Table 2). Unlike the patient in the “recommended” cohort, who spent 6 days in a sub-intensive care unit and 13 days in the ordinary unit, none of the patients in the “control” cohort required admission to sub-intensive care units or an ICU, and all were managed in the ordinary hospital units (Table 2). Thus,

cumulative hospitalization costs were €9.058 and €60.316 in the “recommended” and “control” cohorts, respectively (Figure 2). Only 9.8 (95% CI: 6.1–25.1) patients needed to be treated with the home therapy algorithm to prevent one hospitalization event.

Regarding hospital admission, a sensitivity analysis was also performed after excluding patients who spontaneously began taking paracetamol before the family doctor prescriptions in the “recommended” cohort and the related matched patients in the “control” cohort. Similar to the intention-to-treat analysis, only 1 of the 99 patients (1.01%) in the “recommended” cohort required hospital admission, compared to 10 of the 99 patients (10.1%) in the “control” cohort. The event rate was still significantly lower in the “recommended” than in the “control” cohort (survival analysis for clustered data, $P = 0.0193$).

DISCUSSION

In this observational matched-cohort study we found that COVID-19 patients being treated at home, early after the onset of symptoms, by their family physicians and according to the proposed recommendation algorithm, almost completely prevented the need for hospitalization due to severe worsening of the illness (primary outcome of the study), compared to patients in the “control” cohort, who were treated at home according to their family doctor’s judgment. This resulted in a reduction of over 85% in the length of hospital stays, which translated into a similar percentage of lowered related treatment costs. Thus, the cost-effectiveness of the home recommendation treatment algorithm was remarkable, considering that the early

TABLE 2 | Clinical course of hospitalized patients in the two cohorts.

Cohort	Reason for hospital admission	Hospitalization (days)	Oxygen therapy* (yes/no)	CPAP° (yes/no)	CPAP (days)	Mechanical ventilation (yes/no)	Mechanical ventilation (days)	ICU admission° (yes/no)	ICU admission (days)	Sequelae at discharge (yes/no)
<i>Control</i>										
Control	Interstitial pneumonia	12	Yes	No	–	No	–	No	–	No
Control	Interstitial pneumonia	26	Yes	No	–	No	–	No	–	No
Control	Interstitial pneumonia	4	Yes	No	–	No	–	No	–	No
Control	Interstitial pneumonia	12	Yes	No	–	No	–	No	–	No
Control	Interstitial pneumonia	4	Yes	No	–	No	–	No	–	No
Control	Interstitial pneumonia	13	Yes	No	–	No	–	No	–	No
Control	Interstitial pneumonia	17	Yes	No	–	No	–	No	–	No
Control	Interstitial pneumonia and epigastralgia	6	No	No	–	No	–	No	–	No
Control	Interstitial pneumonia	10	Yes	No	–	No	–	No	–	No
Control	Interstitial pneumonia and epigastralgia	9	Yes	No	–	No	–	No	–	No
Control	Interstitial pneumonia and gastrointestinal symptoms	8	Yes	No	–	No	–	No	–	No
Control	Pulmonary thromboembolism	20	No	No	–	No	–	No	–	No
<i>“Recommended”</i>										
“Recommended”	Interstitial pneumonia	19	Yes	Yes	6	No	–	No	–	No

*Conventional oxygen therapy (oxygen delivered by nasal tube, nasal cannula, or face mask).

°CPAP, continuous positive airway pressure; ICU, intensive care unit.

symptoms in the two cohorts were comparable. In line with this observation, only 9.8 patients needed to be treated to prevent one hospitalization event. These findings, achieved in a larger number of COVID-19 patients, further corroborate the results of our previous matched-cohort study regarding the lower risk of hospital admission in patients treated at home at the onset of illness according to the recommendation algorithm (20), than with other regimens. Similarly, the rate of resolution of major COVID-19 symptoms, including fever, myalgias/arthralgias, headache and cough, was numerically higher in the “recommended” algorithm than in the “control” cohort. Moreover, other symptoms, such as anosmia, ageusia, or fatigue, ceased more frequently and persisted for a shorter period in the “recommended” than in the “control” cohort. Together, these observations suggest that the two regimens targeting early symptoms, not the virus, affected the COVID-19 disease phenotype in different ways, which translated into a remarkably lower need for hospitalization in patients treated

according to the “recommended” algorithm. Moreover, the lower hospitalization rate in this cohort cannot be attributed to limited access to hospitals, since patients in the “recommended” regimen group became ill during the third wave of the pandemic (starting in January 2021), when hospital (human and technical) resources were brought close to but did not reach the limit at which hospitals would have been forced to deny admission of those with severe COVID-19. This was not the case for the “control” cohort, in which most patients reported symptoms during the first stage of the COVID-19 outbreak, when hospitals were under huge pressure, which may have resulted in postponed or denied hospitalization for some patients in need. Thus, the finding that there was a remarkably higher hospitalization rate in the “control” cohort provided additional evidence of the protective effect of the proposed treatment algorithm against hospitalization because of worsening COVID-19 symptoms.

Our recommendation treatment algorithm (17) is based on the idea that it is critical to intervene at home very early

TABLE 3 | Treatment at home in the two study cohorts.

	Recommended treatment cohort (n = 108)	Control cohort (n = 108)	P-value
Relatively selective COX-2 inhibitors	74 (68.52)	4 (3.70)	<i>P</i> < 0.001
Nimesulide	36/74 (48.65)	1/4(25.00)	
Morniflumate	0 (0)	2 (50.00)	
Celecoxib	38/74 (51.35)	0/ (0)	
Etoricoxib	0/ (0)	1/ (25.00)	
Other NSAIDs	34 (31.48)	82 (75.93)	<i>P</i> < 0.001
Aspirin	15/34 (44.12)	5/82 (6.10)	
Ketoprofen	7/34 (20.59)	4/82 (4.88)	
Ibuprofen	10/34 (29.41)	12/82 (14.63)	
Indomethacin	0/ (0)	0/ (0)	
Paracetamol	9/34 (26.47)	74/82 (90.24)	
Corticosteroids	28 (25.93)	7 (6.48)	<i>P</i> < 0.001
Anticoagulants	3 (2.78)	2 (1.85)	<i>P</i> = 1.000
Antibiotics	41 (37.96)	26 (24.07)	<i>P</i> = 0.039
Azithromycin	20/41 (48.78)	7/26 (26.92)	
Amoxicillin and clavulanic acid	0/41 (0)	3/26 (11.54)	
Need of oxygen*	10 (9.26)	2 (1.85)	<i>P</i> = 0.033

Data are n/N (percentages). COX-2, cyclooxygenase-2; NSAIDs, non-steroidal anti-inflammatory drugs.

*Need for oxygen therapy at home. Between-group differences were assessed by Fisher's exact test.

on during the onset of mild/moderate symptoms to avoid progression toward severe COVID-19, which would eventually require hospital admission. Indeed, after initial exposure to SARS-CoV-2, patients typically develop symptoms that indicate an inflammatory process within 5–6 days on average (15, 16), and pro-inflammatory mediators, in particular cytokines, seem to be integral to the initiation, intensification, propagation and worsening of tissue morbidity related to COVID-19 (16, 19, 27). Therefore, our recommended treatment algorithm moved from this pathophysiologic rationale for early COVID-19 events, and focused on the initial use of NSAIDs—which have been shown to reduce pro-inflammatory cytokine levels (18)—during this time frame, that is, after the first 5–6 days of viral incubation, when mild disease symptoms appear and the host immune response against SARS-CoV-2 has been activated. NSAIDs inhibit the cyclooxygenase activity of prostaglandin H synthase 1 and 2, also named COX-1 and COX-2 (28). Relatively selective COX-2 inhibitors (e.g., celecoxib, etoricoxib) (28) may reduce pro-inflammatory cytokine levels, as shown in mice with influenza A infection (TNF- α , G-CSF, and IL-6) (29) and in hospitalized COVID-19 patients (IL-6) (19, 30). The overlap in COX-2 selectivity between coxibs and the more traditional NSAID nimesulide (28) was the rationale for recommending these drugs for the treatment of early COVID-19 at home, unless contraindicated. Adherence to this recommendation was very high (75.3%) in the “recommended” algorithm cohort. On the

TABLE 4 | Major secondary outcomes.

	Recommended treatment cohort (n = 108)	Control cohort (n = 108)	Nominal P-value
Time from symptom onset and start of anti-inflammatory therapy (days)	1.7 \pm 3.3	–	–
Rate of resolution of major symptoms*	105/108 (97.2)	101/108 (93.5)	<i>P</i> = 0.332
Rate of persistence of other symptoms ^o	22/108 (20.4)	69/108 (63.9)	<i>P</i> < 0.001**
Persistence of other symptoms (days)			
<30	6/22 (27.3)	13/69 (18.8)	<i>P</i> = 0.385
30–60	8/22 (36.4)	6/69 (8.7)	<i>P</i> = 0.0043**
>60	8/22 (36.4)	50/69 (72.5)	<i>P</i> = 0.0043**

Data are n/N (percentages) or mean \pm SD, as appropriate.


*Defined as complete recovery from major symptoms, i.e., no fever, SpO₂ >94% and/or no dyspnea, no cough, no rhinitis, no pain (myalgia, arthralgia, chest pain, headache, sore throat), no vertigo, no nausea, vomiting or diarrhea, no sicca syndrome or red eyes.

^oDefined as recovery from major COVID-19 symptoms, but persistence of symptoms such as anosmia, ageusia/dysgeusia, lack of appetite, fatigue.

**Significant after Bonferroni-adjustment for multiple tests.

other hand, in the “control” cohort very few patients were treated with a COX-2 inhibitor, and most received paracetamol. However, this drug, considered an alternative for addressing early-stage COVID-19 symptoms (14), has negligible anti-inflammatory effects (31), in addition to being capable of inducing or worsening glutathione consumption (32, 33). Given the anti-oxidant property of glutathione, it has recently been hypothesized that paracetamol might even exacerbate COVID-19 (32, 33).

Physicians may be reluctant to use NSAIDs, including relatively selective COX-2 inhibitors, due to the known risk of cardiovascular events (34) and the hepatotoxicity of nimesulide, which is admittedly very low when the drug is prescribed at the recommended daily dose and time of administration (35). On the other hand, in a large cohort of over 4,200 patients admitted to the hospital who had taken NSAIDs within the 2 weeks preceding hospital admission, the use of these drugs was not associated with higher mortality or increased severity of COVID-19, as compared to a matched group of NSAID non-users (36). Moreover, another study provided no indication that harm was induced by NSAIDs, as demonstrated by the lack of an increased risk of poorer outcomes in COVID-19 patients given NSAIDs compared with those treated with paracetamol, or NSAID non-users (37). None of the patients in the “recommended algorithm” cohort developed toxicity related to or possibly related to the use of celecoxib or nimesulide. This is in line with the fact that few patients in this cohort received aspirin, which the recommendations propose as alternative therapy when contraindications to celecoxib or nimesulide are highlighted by physicians. Notably, there is evidence that aspirin may reduce plasma levels of pro-inflammatory cytokines (38), and lower the risk of in-hospital mortality in a large cohort of patients



hospitalized with COVID-19 (39), supporting the use of this drug in the early stages of COVID-19 at home when needed. In the future, other NSAIDs, such as indomethacin, which is also known to lower IL-6 (40), could be proposed as an alternative treatment for early COVID-19 symptoms at home, as anticipated by a recent small Indian study (41).

The same pharmacologic rationale was adopted for recommending the use of corticosteroids, known to exert anti-inflammatory effects mainly by inhibiting pro-inflammatory genes that encode for cytokines and chemokines (42). Our proposal clearly suggests only starting corticosteroids several days after the onset of symptoms if fever or musculoskeletal pain persist despite NSAIDs, or when oxygen saturation declines significantly. According to this, in the “recommended algorithm” cohort, corticosteroids were administered only after a median of 7 days after the onset of symptoms and when they fulfilled the proposed criteria for starting this class of drugs, not necessarily limited to patients in need of oxygen supply. This might explain the discrepancy between the number of patients treated with corticosteroids ($n = 28$) and those given oxygen therapy ($n = 10$) in the “recommended” cohort. Despite concerns about the

use of corticosteroids in COVID-19 patients due to the risk of complications and the possible persistence of the virus in the host (43, 44), no side effects related to the use of these drugs were reported in patients in the “recommended” cohort. Based on the large RECOVERY trial (10), WHO recommended systemic corticosteroids only in hospitalized patients with severe COVID-19 who require respiratory support (45). However, there is also some evidence of the benefit of corticosteroids during the early phase of the illness (46, 47), recently corroborated by findings of randomized controlled trials with inhaled corticosteroids in the community (48, 49). The administration of inhaled budesonide within 7 days of the onset of mild COVID-19 symptoms markedly reduced the risk of hospitalization compared to patients receiving the usual care. These results are similar to those achieved in our ‘recommended algorithm’ cohort. Interestingly, the recommendations of the Italian Ministry of Health for the management of COVID-19 patients at home have recently been updated (14) to include corticosteroids for the treatment of early COVID-19 symptoms, according to criteria that are very similar to those proposed in our recommendation algorithm (17).

Despite being recommended by the algorithm, especially for those bedridden or with high D-dimer levels, only a small number of COVID-19 patients in the “recommendation” cohort received a prophylactic dose of LMW heparin. None of them had side effects. Actually, COVID-19 is characterized by dysregulation of the coagulation system and by fibrinolysis that can promote micro- and macro-vascular thrombosis, as well as venous thromboembolic complications, which are sometimes life-threatening (16, 50, 51). Even guidelines (14) suggest that LMW heparin be used at a prophylactic dosage in COVID-19 patients at home in particular instances. Nonetheless, a recent study involving 2,219 non-critically ill, hospitalized COVID-19 patients reported that therapeutic-dose anticoagulation with heparin increased the probability of in-hospital survival compared with standard care thromboprophylaxis, regardless of the patient’s baseline D-dimer levels (52). This finding provides a rationale for studying an initial strategy of therapeutic vs. prophylactic anticoagulation with LMW heparin in COVID-19 patients with moderate symptoms, too, who are also being treated at home.

Similarly, the recommendation for antibiotic treatment was only in case of suspected bacterial pneumonia or suspected secondary bacterial upper respiratory infections, not on a routine basis, which is in line with the UK NICE COVID-19 guidelines for managing patients at home (13). According to these indications, family doctors in the “recommended algorithm” cohort used antibiotics in 37% of their COVID-19 patients. This is not surprising, given that in a systematic review of hospitalized COVID-19 patients, 1,450 of 2,010 individuals (72%) were treated with antibiotics, despite only 8% presenting with evidence of bacterial coinfection (53). Nonetheless, the risk of developing antimicrobial resistance should caution us against using antibiotics indiscriminately.

The non-randomized design is a major limitation of this study, which is observational in nature. Nonetheless, a

comparative analysis of patient cohorts in everyday clinical practice, with adjustments for possible confounding biases, may offer a suitable alternative to the recommended clinical trials to evaluate the effectiveness of different therapeutic regimens (54, 55). Moreover, the matched-cohort study protocol with a statistical plan was predefined and the analyses were performed accordingly. There is the additional limitation that the collection of outcome information in the “control” cohort was conducted through interviews and questionnaires related to events that had occurred before the survey. This was not the case for the “recommended algorithm” cohort, where family doctors gathered data. However, in both cohorts the date of hospital admission (primary outcome) and data regarding the course of hospitalization were well-documented in the hospital discharge letter. Moreover, further evidence of the observed difference between the hospital admission rates for the two cohorts is offered by the results of the additional explorative analysis of 3,368 patients (i.e., 3,260 from the control ORIGIN database and 108 from the “recommended algorithm” cohort), which confirmed a significantly lower rate of hospitalization in the “recommended algorithm” than in the “control” group. Moreover, a multivariable logistic regression model based on the 3,368 patients further supported the primary findings regarding hospitalization (**Supplementary Table S3**).

On the other hand, the COVER 2 study formally tested outcomes for COVID-19 patients managed by their family physicians according to a therapy recommendation algorithm that targets early symptoms, based on the pathophysiology of the illness and the related pharmacologic rationale. This is a strength of the COVER 2 study, since none of the recently proposed recommendations for family doctors in the community on how to treat COVID-19 patients have been formally evaluated in terms of whether they can limit the progression of mild/moderate symptoms from the onset of the disease to the need for hospital admission.

In conclusion, we have documented that simple, reasoned treatments for the early-phase symptoms of COVID-19 that can be administered at home, collected in a recommendation algorithm for family doctors, are beneficial in clinical practice, since they can help to avoid or limit deterioration of the disease to the point of hospitalization, in addition to having public health implications. Our findings also have important implications for patient quality of life, since adopting the treatment recommendation approach reduced the rate and shortened the duration of symptoms, such as loss of taste or smell, and fatigue, which might otherwise persist for several months (56). Future randomized studies will be required for the consolidation of these observational findings on the potential benefit of the proposed treatment recommendation algorithm.

DATA AVAILABILITY STATEMENT

Sharing individual participant data with third parties was not specifically included in the informed consent form of the study,

and unrestricted diffusion of such data may pose a potential threat of revealing participants’ identities, as permanent data anonymization was not carried out (patient records were instead de-identified per protocol during the data retention process). To minimize this risk, individual participant data that underlie the results reported in this article will be available after three months and for up to five years following article publication. The researchers shall submit a methodologically sound proposal to AP (annalisa.perna@marionegri.it), Head of the Laboratory of Biostatistics of the Department of Renal Medicine of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS. To gain access, data requestors will need to sign a data access agreement and obtain the approval of the local ethics committee. Further enquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethical Committee of Insubria (Varese, Italy; 27 July 2021) and registered at the ClinicalTrials.gov (NCT04854824). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

GR, FS, and PR had the original idea. NP and GR wrote the draft version of the manuscript. EC, SP, CM, EP, MP, GP, UC, and FS contributed to patient identification. NR helped with data collection and management. AP and TP performed the statistical analyses. NP, PR, and GR developed the final version of the manuscript. GR and NP took responsibility for the submission for publication. No medical writer was involved. All authors contributed to the article and approved the submitted version.

FUNDING

This study was partially supported by a generous donation from QuattroR SGR SpA to the Istituto di Ricerche Farmacologiche Mario Negri IRCCS. The QuattroR SGR SpA did not have any role in study design, in the collection, analysis and interpretation of data, in writing the report, or in the decision to submit the paper for publication.

ACKNOWLEDGMENTS

The authors wish to thank Kerstin Mierke for help with English language editing of the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmed.2022.785785/full#supplementary-material>

REFERENCES

- Johns Hopkins CSSE. COVID-19 Map - Johns Hopkins Coronavirus Resource Center. Available online at: <https://www.coronavirus.jhu.edu> (accessed September 1, 2021).
- Gómez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19. *Vaccines*. (2021) 9:243. doi: 10.3390/vaccines9030243
- Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. (2020) 26:1017–32. doi: 10.1038/s41591-020-0968-3
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3
- Carfi A, Bernabei R, Landi F, Gemelli against COVID-19 post-acute care study group. persistent symptoms in patients after acute COVID-19. *JAMA*. (2020) 324:603–5. doi: 10.1001/jama.2020.12603
- Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic. *JAMA*. (2020) 324:1292–5. doi: 10.1001/jama.2020.16747
- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. *JAMA*. (2020) 323:1824–36. doi: 10.1001/jama.2020.6019
- WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. *JAMA*. (2020) 324:1330–41. doi: 10.1001/jama.2020.17023
- Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. *Science*. (2020) 367:1412–3. doi: 10.1126/science.367.64.85.1412
- RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med*. (2021) 384:693–704. doi: 10.1056/NEJMoa2021436
- World Health Organization. “Solidarity” Clinical Trial for COVID-19 Treatments. (2020). Available online at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments> (accessed March 17, 2021).
- Kim PS, Read SW, Fauci AS. Therapy for early COVID-19: a critical need. *JAMA*. (2020) 324:2149–50. doi: 10.1001/jama.2020.22813
- Available online at: <https://www.nice.org.uk/guidance/ng165> (accessed April 3, 2020).
- Ministero della Salute. *Gestione domiciliare dei pazienti con infezione da SARS-CoV-2, aggiornata al 26 aprile 2021*. Available online at: https://www.salute.gov.it/portale/news/p3_2_1_1.jsp?lingua=italiano&menu=notizie&p=null&id=5449 (accessed September 1, 2021).
- Oberfeld B, Achanta A, Carpenter K, Chen P, Gillette NM, Langat P, et al. SnapShot: COVID-19. *Cell*. (2020) 181:954–4.e1. doi: 10.1016/j.cell.2020.04.013
- Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. *Nat Rev Nephrol*. (2021) 17:46–64. doi: 10.1038/s41581-020-00357-4
- Suter F, Perico N, Cortinovis M, Remuzzi G. A recurrent question from a primary care physician: how should I treat my COVID-19 patients at home? An update *Clin Med Invest*. (2020) 5:1–9. doi: 10.15761/CMI.1000218
- Baghaki S, Yalcin CE, Baghaki HS, Aydin SY, Daghan B, Yavuz E. COX2 inhibition in the treatment of COVID-19: review of literature to propose repositioning of celecoxib for randomized controlled studies. *Int J Infect Dis*. (2020) 101:29–32. doi: 10.1016/j.ijid.2020.09.1466
- Prasher P, Sharma M, Gunupuru R. Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy. *Drug Dev Res*. (2021) 82:469–73. doi: 10.1002/ddr.21794
- Suter F, Consolaro E, Pedroni S, Moroni C, Pastò E, Paganini MV, et al. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: a retrospective observational matched-cohort study. *EClinicalMedicine*. (2021) 37:100941. doi: 10.1016/j.eclinm.2021.100941
- ERA-EDTA Council, ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. *Nephrol Dial Transplant*. (2021) 36:87–94. doi: 10.1093/ndt/gfaa314
- Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA Intern Med*. (2020) 180:1345–55. doi: 10.1001/jamainternmed.2020.3539
- Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. *Nat Rev Nephrol*. (2020) 16:705–6. doi: 10.1038/s41581-020-00349-4
- Parsons LS. Performing a 1:N case-control match on propensity score. *SAS SUGI*. (2004) 29:165–29.
- Garrido MM, Kelley AS, Paris J, Roza K, Meier DE, Morrison RS, et al. Methods for constructing and assessing propensity scores. *Health Serv Res*. (2014) 49:1701–20. doi: 10.1111/1475-6773.12182
- Pocock SJ. *Clinical Trials: A Practical Approach*. Chichester: Wiley (1983). Ch. 14.
- Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. *Med Mal Infect*. (2020) 50:382–3. doi: 10.1016/j.medmal.2020.04.002
- FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. *N Engl J Med*. (2001) 345:433–42. doi: 10.1056/NEJM200108093450607
- Carey MA, Bradbury JA, Reboloso YD, Graves JP, Zeldin DC, Germolec DR. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. *PLoS ONE*. (2010) 5:e11610. doi: 10.1371/journal.pone.0011610
- Ong SWX, Tan WYT, Chan Y-H, Fong S-W, Renia L, Ng LF, et al. Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. *Clin Transl Immunol*. (2020) 9:e1159. doi: 10.1002/cti2.1159
- Ghanem CI, Pérez MJ, Manautou JE, Mottino AD. Acetaminophen from liver to brain: new insights into drug pharmacological action and toxicity. *Pharmacol Res*. (2016) 109:119–31. doi: 10.1016/j.phrs.2016.02.020
- Pandolfi S, Simonetti V, Ricevuti G, Chirumbolo S. Paracetamol in the home treatment of early COVID-19 symptoms: a possible foe rather than a friend for elderly patients? *J Med Virol*. (2021) 93:5704–6. doi: 10.1002/jmv.27158
- Stestili P, Fimognari C. Paracetamol-induced glutathione consumption: is there a link with severe COVID-19 illness? *Front Pharmacol*. (2020) 11:579944. doi: 10.3389/fphar.2020.579944
- Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet*. (2013) 382:769–79. doi: 10.1016/S0140-6736(13)60900-9
- Donati M, Conforti A, Lenti MC, Capuano A, Bortolami O, Motola D, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. *Br J Clin Pharmacol*. (2016) 82:238–48. doi: 10.1111/bcp.12938
- Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. *Lancet Rheumatol*. (2021) 3:e498–506. doi: 10.1016/S2665-9913(21)00104-1
- Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. *Clin Microbiol Infect*. (2020) 26:1259.e5–7. doi: 10.1016/j.cmi.2020.06.003
- Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. *Circulation*. (1999) 100:793–8. doi: 10.1161/01.CIR.100.8.793
- Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A, Jackson AM, et al. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. *Anesth Analg*. (2021) 132:930–41. doi: 10.1213/ANE.00000000000005292

40. Bour AM, Westendorp RG, Laterveer JC, Bollen EL, Remarque EJ. Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect. *Exp Gerontol.* (2000) 35:1017–24. doi: 10.1016/S0531-5565(00)00128-5
41. Ravichandran R, Purna P, Vijayaragavan S, Kalavakollu RT, Gaidhane S, Kumar RK. Efficacy and safety of indomethacin in Covid-19 patients. *MedRxiv.* (2021) 1–25. doi: 10.22541/au.161000568.81171409/v1
42. Cruz-Topete D, Cidlowski JA. One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. *Neuroimmunomodulation.* (2015) 22:20–32. doi: 10.1159/000362724
43. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med.* (2006) 3:e343. doi: 10.1371/journal.pmed.0030343
44. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid Therapy for critically ill patients with middle east respiratory syndrome. *Am J Respir Crit Care Med.* (2018) 197:757–67. doi: 10.1164/rccm.201706-1172OC
45. Lamontagne F, Agoritsas T, Siemieniuk R, Rochwerg B, Bartoszko J, Askie L, et al. A living WHO guideline on drugs to prevent covid-19. *BMJ.* (2021) 372:n526. doi: 10.1136/bmj.n526
46. Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? *Ecancermedalscience.* (2020) 14:1023. doi: 10.3332/ecancer.2020.1023
47. Lee K-Y. Pneumonia, acute respiratory distress syndrome, and early immunomodulator therapy. *Int J Mol Sci.* (2017) 18:388. doi: 10.3390/ijms18020388
48. Ramakrishnan S, Nicolau DV, Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. *Lancet Respir Med.* (2021) 9:763–72. doi: 10.1016/S2213-2600(21)00160-0
49. Yu L-M, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet.* (2021) 398:843–55. doi: 10.1016/S0140-6736(21)01744-X
50. Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? *Am J Physiol Renal Physiol.* (2020) 318:F1454–62. doi: 10.1152/ajprenal.00160.2020
51. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. *J Clin Virol.* (2020) 127:104362. doi: 10.1016/j.jcv.2020.104362
52. ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. *N Engl J Med.* (2021) 385:790–802. doi: 10.1056/NEJMoa2105911
53. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. *Clin Infect Dis.* (2020) 71:2459–68. doi: 10.1093/cid/ciaa530
54. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *Am J Epidemiol.* (2003) 158:915–20. doi: 10.1093/aje/kwg231
55. Vandembroucke JP. Observational research, randomised trials, and two views of medical science. *PLoS Med.* (2008) 5:e67. doi: 10.1371/journal.pmed.0050067
56. Nehme M, Braillard O, Chappuis F, Courvoisier DS, Guessous I, CoviCare Study Team. Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting. *Ann Intern Med.* (2021) 174:1252–60. doi: 10.7326/M21-0878

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Consolaro, Suter, Rubis, Pedroni, Moroni, Pastò, Paganini, Pravettoni, Cantarelli, Perico, Perna, Peracchi, Ruggenenti and Remuzzi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.